跳到主要內容

臺灣博碩士論文加值系統

(44.222.189.51) 您好!臺灣時間:2024/05/18 17:27
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:派保莉
研究生(外文):Pauline Paoli
論文名稱:企業社會責任策略之研究-以製藥產業為例
論文名稱(外文):A content analysis based on the comparison of three pharmaceutical companies regarding corporate social responsibility
指導教授:鄭佳綾鄭佳綾引用關係
口試委員:曹修源林谷峻
口試日期:2013-04-12
學位類別:碩士
校院名稱:輔仁大學
系所名稱:國際創業與經營管理學程碩士在職專班
學門:商業及管理學門
學類:企業管理學類
論文種類:學術論文
論文出版年:2013
畢業學年度:101
語文別:英文
論文頁數:57
外文關鍵詞:Corporate social responsibility
相關次數:
  • 被引用被引用:0
  • 點閱點閱:297
  • 評分評分:
  • 下載下載:72
  • 收藏至我的研究室書目清單書目收藏:0
Purpose: The purpose of this research paper is to analyze the similarities and differences regarding the corporate social responsibility (CSR) strategy of three selective pharmaceutical companies located in three different countries, which are Merck (USA), GlathoSmithKline (GSK) (UK), and Ranbaxy (India).
Design/methodology/approach: A content description of three selected pharmaceutical companies regarding mission and vision, values, and ethical issues that both companies had to face in order to analyze the similarities and differences of the three companies.
Findings: Pharmaceutical companies have been recognized as the leader in sustainability mainly because of the continuous interest of the media and the public regarding healthcare. However, the three pharmaceutical companies
4
selected located in three different continents pursue different strategy to achieve their corporate’s goals.
Originality/value: There has been much emphasis on how pharmaceutical companies are focusing their strategy on CSR, however no research could be found on how strategy differ regarding pharmaceutical companies from three different countries. This paper analyses the similarities and differences of three selected pharmaceutical companies located in United States, United Kingdom, and India regarding their strategy toward CSR.
ACKNOWLEDGEMENT ................................................................................................................. 2
ABSTRACT ...................................................................................................................................... 3
CHAPTER ONE: INTRODUCTION .............................................................................................. 8
1.1 Research Background and Motivation .............................................................. 8
1.2 Research Purpose ................................................................................................ 9
1.3 Scope and Limitation ........................................................................................ 10
1.4 Thesis Framework ............................................................................................. 10
CHAPTER TWO: LITERATURE REVIEW .............................................................................. 12
2.1 Definition of CSR ............................................................................................... 12
2.2 CSR and the Pharmaceutical Industry ........................................................... 13
2.3 The Balance Scorecard Method (BSC) ............................................................ 15
CHAPTER THREE: METHODOLOGY ..................................................................................... 17
3.1 Content Analysis ................................................................................................ 17
3.2 Conceptualization of Coding Category ........................................................... 19
CHAPTER FOUR: COMPANIE’S ANALYSIS .......................................................................... 21
4.1 Merck .................................................................................................................. 21
4.1.a Company’s overview ........................................................................................................................... 21
4.1.b Mission and Vision .............................................................................................................................. 22
4.1.c Values ................................................................................................................................................. 23
4.1.d Actions ............................................................................................................................................... 24
4.1.e Ethical Issues ...................................................................................................................................... 26
4.2 GSK ..................................................................................................................... 27
6
4.2.a Company’s overview ........................................................................................................................... 27
4.2.b Mission and vision ............................................................................................................................... 28
4.2.c Values ................................................................................................................................................. 29
4.2.d Actions ............................................................................................................................................... 30
4.2.e Ethical Issues ...................................................................................................................................... 32
4.3 Ranbaxy .............................................................................................................. 33
4.3.a Company’s overview ........................................................................................................................... 33
4.3.b Mission and vision ............................................................................................................................... 34
4.3.c Values ................................................................................................................................................. 35
4.3.d Actions ............................................................................................................................................... 35
4.3.e Ethical issues ...................................................................................................................................... 37
CHAPTER FIVE: RESULTS ........................................................................................................ 38
5.1. Companies’ size ................................................................................................ 38
5.2. Mission and vision ............................................................................................ 39
5.3. Values ................................................................................................................. 43
5.4. Actions ............................................................................................................... 45
5.5. Ethical Issues ..................................................................................................... 50
CHAPTER SIX: CONCLUSION ................................................................................................... 53
6.1. Research findings and contributions .............................................................. 53
6.2. Recommendations for further studies ............................................................ 54
REFERENCES ............................................................................................................................... 55
1. Adams, M. (2010). "Merck's Vioxx Scandal Widens: Drug Maker Knew Vioxx Was Deadly for Years before Risk Was Made Public (opinion)." NaturalNews.
2. Banco, M.C. and Rodrigues, L. (2006), “Corporate social responsibility and resource-based perspectives”, Journal of Business Ethics, Vol. 69. p.111-132.
3. Brammer, S., Jackson, G., Matten, D. (2012), “Corporate social responsibility and institutional theory: new perspective on private governance”, Soci Economic Review.
4. Corpwatch (2012), “The pharmaceutical industry” http://www.corpwatch.org/.
5. Dahksrud A., (2006), “How Corporate Social Responsibility is defined: an Analysis of 37 definitions”. Wiley InterScience Publishers.
6. Epps, J. and Solomon, F. (2000), “Adding social value through accountability in mineral development”, paper presented at the AusIMM Annual Conference, Sydney, p. 1.
7. Grantham, S and Vieira, E.T. Jr (n.d), “Profit status as a context cue for establishing organizational credibility”, Journal of Communications Studies (in press).
8. GSK (2013), http://www.gsk.com/.
9. Kaye, L. (2013), "The Overlooked Sustainability Leaders in Business." Triple Pundit RSS.
10. Knoepfel, I. (2001), “Dow Jones sustainability group index: a global benchmark for corporate sustainability”, Corporate Environment Strategy, Vol.8. No. 1, p.7.
11. Larkin, C. (2011) "FDA Is Reviewing Ranbaxy's Corrective Plan on Drugs to the U.S." EMA & FDA Global HIV News / European AIDS Treatment Group.
56
12. Lee, M., Kohler, J. (2010), “Benchmarking and transparency: Incentives for the pharmaceutical industry’s corporate social responsibility”.
13. Leonard, T. and Schneider, J. (2004), “Sustainability in the pharmaceutical industry”, Corporate Environmental Strategy: International journal for Sustainable Business, Vol. 11. No. 5, p. 119-128.
14. Luo, X, and Bhattacharya, C.B. (2006), “ Corporate social responsibility, customer satisfaction, and market value”, American Marketing Association, Vol 17. p. 1-18.
15. Merck (2013), http://www.merck.com/index.html.
16. Mohin, T. (2012). "The Top 10 Trends in CSR for 2012." Forbes. Forbes Magazine.
17. New York Times (2008), “Executive charged with lying in Plavix case”, April 23.
18. Nielsen, A.E. and Thomsen, C. (2007), “Reporting CSR – what and how to say it?”, Journal of Corporate Communications, Vol. 12. No. 1, p. 25-40.
19. Pasternak, A., M. Gordian, and P. Cichocki. (2013), "Bridging the Shareholder Return Gap in Big Pharma." Bain & Company.
20. Ranbaxy (2013), http://www.ranbaxy.com/.
21. Schneider Jennifer L., Wilson Anna, Rosenbeck Joseph M., (2010), “Pharmaceutical companies and sustainability: an analysis of corporate reporting’, Benchmarking: An International Journal, Vol 17. Iss: 3 p. 421 – 434.
22. Shepherd, R. (2012), "GlaxoSmithKline Pleads Guilty In Fraud Case Over Failure To Report Safety Data." Medical News Today.
23. Sones Morgan, Grantham Susan, Vieira Edward T., (2009), “Communicating CSR via pharmaceutical company web sites: Evaluating message frameworks for external and internal stakeholders”, Corporate Communications: An international Journal, Vol. 14. Iss: 2 p. 144 – 157.
57
24. Tolve, A. (2011), "Sales & Marketing." Pharma and CSR: Why Good Deeds Are Good Business.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top